FÁRMACO
N
TR (%)
SLPm (m)
SGm (m)
Meta-Análisis 2015
NA
1244
10.5
7.4
13.4
PAE Sunitinib
Sunitinib
505
11%
6.0
12.2
RAPTOR
Everolimus
88
1
4.1
21.4
ESPN
Sunitib
Everolimus
68
9
2.8
6.1
4.1
16.2
14.9
ASPEN
Sunitinib
Everolimus
108
18
9
8.3
5.6
31.5
13.2
RECORD-3
Sunitinib
Everolimus
66
7.2
5.1
Vera-Badillo FE, et al. Eur Urol 2015;67:740.
Gore ME, et al. Br J Can 2015, 113(1):12.
Escudier B, et al. Eur J Cancer 2016;69:226.
Tannir N, et al. Eur Urol 2016;69:866.
Armstrong AJ, et al. Lancet Oncol 2016;17:378.
Motzer RJ, et al. J Clin Oncol 2014;32(25):2765.
PAZOPANIB: VIDA REAL.
1ª línea. No célula clara
